Chapter One
Introduction and literature review

1.1. Introduction

Under normal conditions, red cell production and circulating red cell mass (CRM) remain at constant level regulating by the erythropoietic mechanism, which function to meet body’s oxygen requirements, if the red cell production and circulating red cell mass are either excessively decreased or increased, significant clinical problems occur. (Martin, et al. 1998)

Anemia is a decrease in number of red blood cells (RBCs) or less than normal quantity of hemoglobin in the blood. However, it can include decreased oxygen binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency (Barbara 1993; Hoffbrand, et al. 2004).

Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiological mechanism, and discernible clinical spectra, to mention a few. The three main classes of anemia include, excessive blood loss, excessive blood cell destruction or deficient red blood cell production. (Pallister, 1994)

Most commonly, people with anemia report nonspecific symptoms of feeling of weakness, fatigue, general malaise and sometimes poor concentration. In very severe anemia, the body may compensate for the lack of oxygen carrying capability of the blood by increasing cardiac output. The patient may
have symptoms related to this, such as palpitation, angina, and symptom of heart failure (Fauci, 2008).
Causes of anemia may be classified as impaired red cell production, increased red cell destruction (hemolytic anemia), blood loss and fluid overload (hypervolemia) (Dacie and Lewis, 2001).
Anemia is typically diagnosed by complete blood count test. Apart from reporting the number of red blood cells and the hemoglobin level, the automatic counters also measure the size of the red blood cell by cytometry, which is an important tool in distinguishing between the causes of anemia. Examination of stained blood film using microscope can be helpful. In modern counter, four parameters (RBCs count, hemoglobin concentration, MCV, and RDW) are measured, allowing others (HCT, MCH, MCHC) to be calculated, and compared to values adjusted for age and sex. Some counters estimate hematocrit from direct measurements. (Obstet Gynecol, 2008)
1.2. Literature Review:

1.2.1. Definition of anemia:

Anemia is defined as reduction in the hemoglobin concentration of the blood. Although normal values vary between laboratories, typical value would be less than 13.5g/dl in adult males and less than 11.5g/dl in adult females. (Hoffbrand, *et al.* 2004)

If hemoglobin is not adequate to carry oxygen, hypoxia occurs. The decreased oxygen in the body tissues triggers the production of the glycoprotein hormone erythropoietin (EPO) by the kidney, to estimate the bone marrow for releasing immature erythrocytes such as reticulocytes, capable of carrying a significant amount of oxygen, and also increases the rate of erythroid cell production and maturation (Stevens, 1997).

1.2.2. Signs and symptoms of anemia:

Signs and symptoms in anemic patient are due to the anemia itself or the disorder causing the anemia (Firkin, *et al.* 2002).

Most commonly people with anemia report nonspecific symptoms of a feeling of a weakness, fatigue, general malaise.
and sometimes poor concentration. They may also report dyspnoea (shortness of breath) on exertion. In very severe anemia, the body may compensate for the lack of oxygen carrying capability of the blood by increasing cardiac output. The patient may have symptoms related to this, such as palpitation, angina pectoris or intermittent claudication of the legs symptoms of heart failure. (Hoffbrand, et al. 1995)

Symptoms referable to the nervous system are common in severe anemia particularly in older patient who have some degree of cerebrovascular disease. These symptoms include faintness, giddiness, headache, roaring, banging in the ears, spot before the eyes, lack of concentration, drowsiness, numbness and coldness (Firkin, et al. 2002).

Signs may be divided into general and specific. the general signs include pallor of mucous membranes which occurs if the hemoglobin level is less than 9-10g/dl. Skin colour is not a reliable sign. A hyperdynamic circulation may be present with tachycardia, and abounding pulse (Hoffbrand, et al. 1995).

The specific signs are associated with particular types of anemia e.g Koilonychia (spoon nails) with iron deficiency, jaundice with hemolytic anemias or megaloblastic anemia, Leg ulcers with sickle cell and other hemolytic anemias, bone deformities with thalassemia major and other sever congenital hemolytic anemias (Hoffbrand, et al.1995).

1.2.3. Classification of anemia:
1.2.3.1. Etiological classification:
1. Decreased or impaired production of red blood cells due to:
   - Bone marrow damage, infiltration, and atrophy which occur in leukemia, aplastic anemia, pure red cell aplasia, lymphoma and multiple myeloma.
   - Decreased erythropoietin, which occurs in inflammatory process, anemia of chronic disease and hypothyroidism.
   - Defect in globin synthesis, which occurs in alpha and Beta thalassemia
   - Vitamins and minerals deficiency, which occur in iron deficiency, vitamin B₁₂ deficiency, and folic acid deficiency.
   - Ineffective erythropoiesis, which occurs in congenital dyserythropoietic anemia (Mazza, 1995).

2. Increased cell red destruction:
   A. intrinsic defects within the red blood cell which occur in:
      - Hereditary-membrane defect like spherocytosis and stomatocytosis.
      - Hereditary enzyme defect like Glucose-6- phosphate dehydrogenase deficiency and pyruvate kinase.
      - Hereditary defective globin synthesis like B-thalassemia major and hemoglobin E disease.
      - Hereditary-Hemoglobin like sickle cell disease and hemoglobin C disease
   B. Extra corpuscular causes: non immune acquired hemolytic anemias:
      - Chemical: e.g toxin, venom
• Physical: e.g trauma-disorder-causing fragmentation, burns
• Infections: e.g parasitic infection (malaria)
C. Extra coruscular causes: immune hemolytic anemias:
• Iso immune antibodies
• Auto immune antibodies
D. Miscellaneous:
• Anemia of liver disease
• Sulfa hemoglobinemia
• Methemoglobinemia

3. acute blood loss (Mazza, 1995).

1.2.3.2. Morphological classification:
The morphological classification of anemia can be established using red cell indices and direct examination of their morphology. Red cell morphology observed and described using a properly prepared and stained blood film. Anemia can be classified according to erythrocyte size and hemoglobin content and it depend on (MCV) mean cell volume in to:

1. Normocytic normochromic
2. Microcytic hypochromic

Although this format has been widely used for many years, problems sometimes occur (Dallman, et al. 1984). In prior years, indices derived from manually determined red cell measurements were questioned because of high level of
procedural variability and error, especially in manual red cell count (Freedman and Marcus, 1980).

**Table (1.1) : Morphological classification of anemia** (Martin, *et al.* 1998):

<table>
<thead>
<tr>
<th>Classification</th>
<th>Common in</th>
<th>Occasionally in</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.microcytic:</td>
<td>Iron deficiency anemia</td>
<td>Anemia of chronic disease</td>
</tr>
<tr>
<td>MCV less than 80fl</td>
<td>Thalassemia</td>
<td>Hemoglobinopathy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypoproliferative anemia</td>
</tr>
<tr>
<td>2.macrocytic:</td>
<td>Folic acid deficiency</td>
<td>Vitamin B12 deficiency</td>
</tr>
<tr>
<td>MCV more than 100fl</td>
<td>Vitamin B12 deficiency</td>
<td>Liver disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hemolytic anemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Blood loss</td>
</tr>
<tr>
<td>3.normocytic:</td>
<td>Hemolytic anemia</td>
<td>Early iron deficiency</td>
</tr>
<tr>
<td>MCV (80-100)fl</td>
<td>Hemoglobinopathy</td>
<td>Refractory anemia</td>
</tr>
<tr>
<td></td>
<td>Anemia of chronic disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blood loss anemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acquired sidroblastic anemia</td>
<td></td>
</tr>
</tbody>
</table>

A normal red cell indices should be confirmed by microscopic examination of blood films. The most important measurements are of red cell size (mean cell volume MCV), mean cell hemoglobin MCH, and mean cell hemoglobin concentration
MCHC. Anemia with raised, normal, and reduced red cell size (MCV) are termed: macrocytic, normocytic, and microcytic respectively. Anemia associated with reduced hemoglobin concentration with red cell termed hypochromia, and those with normal MCH are termed normochromic (Howard and Hamilton, 2008).

The presence of abnormally shaped erythrocytes (poikilocytes) may suggest a specific disease or cause (Firkin, et al. 1989).

1.2.3.3. Physiological classification of anemia:

The physiological classification is based on the ability of the bone marrow to respond anemia with increased erythropoiesis. It involves assessing erythrocyte production using the reticulocytes count either proportional (%) or absolute and calculation of reticulocyte production index (RPI) (Martin, et al. 1998)

Anemia is classified in to:
1. Ineffective erythropoiesis (RPI lower than 2.0)
2. Effective erythropoiesis (RPI more than 2.0)
3. Less common group of anemia is that association with hemoglobin variant with decreased oxygen affinity. (Hillman and finch, 1985)

1.2.4. Causes of anemia:

Anemia can be generally regarded to result from impaired red cell production, excessively rapid red cell destruction (hemolytic anemia), blood loss ,fluid over load, diet, and social

1. Impaired red cell production:
- Inadequate supply of nutrients essential for erythropoiesis such as iron deficiency, vitamin B12 deficiency, and folic acid deficiency.
- Depression of erythropoietic activity.
- Anemia associated with chronic disorders such as infection, connective tissue disorders, and disseminated malignancy.
- Anemia associated with renal failure by insufficient erythropoietin production.
- Aplastic anemia, affecting all kind of blood cells
- Anemia due to replacement of normal bone marrow by leukemia, lymphoma, and myeloproliferative disorders.
- Anemia due to inherited disorders such as thalassemia (Firkin, et al. 2002)

2. Increased destruction of red cell:
Anemias of increased red cell destruction are generally classified as hemolytic anemias. These are generally featuring jaundice and elevated lactate dehydrogenase (LDH) levels. The destruction due to:
A. Intrinsic defect in red cell
B. Extrinsic defect in red cell like antibody mediated (Lee, et al. 1993)

3. blood loss:
Overt blood loss is important cause of anemia and through history should be taken to establish weather epistaxis, rectal bleeding, menorrhagia or recurrent bleeding from other sites of the body.((Firkin, et al. 2002)
4. Fluid over load:
Fluid over load (hypervolemia) causes decreased hemoglobin concentration and anemia. General causes of hypervolemia include excessive sodium or fluid intake, sodium or water retention, also include anemia of pregnancy. (Lee, et al. 1993)

5. Diet:
Inadequate diet can contribute to iron deficiency anemia and is generally the basis of megaloblastic anemia due to folic acid deficiency (Firkin, et al. 2002).

6. Social history:
Alcoholism is increasingly recognized as associated with nutritional folic acid deficiency (Firkin, et al. 2002).

1.2.5. Frequency of anemia:
The prevalence of anemia and the etiologies vary in different population. In developed countries most studies have been performed, anemia is more common in women than in men, particularly susceptible groups include pregnant women, children under 5 years and elderly. The majority of cases in younger people are caused by iron deficiency. In the developing countries, factors influencing the prevalence of anemia include: climate, socio-economic conditions and most importantly the incidence of coexistent diseases (Howard and Hamilton, 2008).

1.2.6. Diagnosis of anemia:
The first step in diagnosis of anemia is a physical examination and history of patient. A documented history of anemia that reaches back to childhood is highly suggestive of hereditary disorders especially congenital hemolytic anemia. Race can also be an important clue, because many of the hemoglobinopathies and enzyme deficiency states follow ethnic lines. The doctor should examine the patient carefully, especially checking for swollen lymph node, an enlarged spleen, pale skin and nail colour (Hillman, et al. 2005).

The routine hematology laboratory offers several tests such as the CBC and reticulocyte count. A larger number of more specific tests are used to confirm the diagnosis of specific anemic condition (Hillman, et al. 2005).

1. **Complete blood count (CBC):**  
   CBC test is a panel of tests that measure red blood cells, white blood cells, and platelets. For diagnosis of anemia, the CBC provides critical information on the size, volume, and shape of red blood cells. CBC result includes measurements of hemoglobin, hematocrit, mean corpuscular volume, and hemoglobin content. These measurements are provided by any of the common automated counters (Hillman, et al. 2005).

   In addition to the MCV, MCH, and MCHC, automated counters provide an index of the distribution of red blood cell volumes, termed the red cell distribution width (RDW) (Hillman, et al.
RDW is useful in early classification of anemias because it becomes abnormal earlier in nutritional deficiency anemias like IDA and useful in distinguishing between IDA (high RDW) and uncomplicated heterozygous thalassemia (normal RDW) (Lee, et al. 1998)

2. Reticulocyte count:
A reticulocyte count permits effective assessment of RBCs production by the bone marrow. Reticulocytes are young RBCs that have just left the marrow but still contain residual RNA, they remain for 1-15 days in the blood, the normal range is 0.5-2% (Bernadette and Rodak, 1995).

3. Blood smear examination:
The most important evaluation in the workup of an anemia is to examine the peripheral blood smear, giving particular attention to the RBCs as to variation in size, shape, colour content, and inclusion. Normal RBCs on wright’s stained blood film are nearly uniform in size, being 7.0-7.9 µm in diameter, small or microcytic RBCs are less than 6µm in diameter, and large or macrocytic RBCs are more than 9 µm in diameter. Certain abnormalities of diagnostic value such as sickle shaped RBCs or malaria parasites can be detected only by studying the RBCs on peripheral blood smear carefully.(Bernadette and Rodak, 1995)
The types of WBCs should be differentiated and any WBCs abnormalities should be noted. The number of platelets per oil immersion field (Oifs) must be detected by counting 10
consuctive Oifs in an area of smear in which the RBCs are separated gently touch one another. (Bernadette and Rodak, 1995)

4. Bone marrow examination:
This may be performed by aspiration and trephine biopsy. During bone marrow aspiration, a needle is inserted into the marrow and sucked in to a syringe. This is then spread on a slide and stained by the usual Romanwsky technique for microscopy. Great deal of morphological information can be obtained by examining aspirate slides. A trephine biopsy provides slides core of bone including marrow and is examined as histopathological specimen after fixation in formalin, decalcification and sectioning (Hoffbrand, et al., 1995).

After the hematologic laboratory studies are completed, the anemia may be classified morphologically. Particularly special testes may be indicated on the basis of morphologic type of anemia present, such as serum iron, serum ferrtin if microcytic anemia is present (Greer, et al., 2003).

1.2.7. Macrocytic anemia:
The macrocytic anemias are characterized not only by an increase the volume of cell, as measured by MCV, but in all dimension of cell including diameter and thickness. The amount of hemoglobin in each cell increases in proportion to size; consequently, the MCHC remains normal (Lee, et al. 1993).
By means of morphological and biochemical criteria, macrocytic anemias can be divided into two groups:
• Megaloblastic anemias
• Non megaloblastic anemias (Lee, et al. 1993)

These classifications are based on the appearance of developing erythroblast in the bone marrow (Hoffbrand, et al. 2001).

Megaloblastic anemia is so named because it is characterized by the appearance in the bone marrow of morphologically abnormal nucleated red cell precursors, which Ehrlich in 1880 called megaloblasts. Megaloblasts are abnormal in function as well as in appearance with the result that the mature red cells formed from them are abnormal in size and shape, the prominent abnormality being macrocytosis (Firkin, et al. 1989). Megaloblastic anemias are defined by the presence of these cells or by other evidence of defective DNA synthesis (Lee, et al. 1993)

Nonmegaloblastic anemias are not united by a common pathogenetic mechanism; they simply represent macrocytic anemias in which DNA synthesis is unimpaired. They are macrocytic only occasionally; often they are normocytic. When macrocytosis is found, it tends to be mild; the MCV usually ranges from 100 to 110fl and rarely exceeds 120fl (Lee, et al.1993).

Macrocytosis is a common finding in clinical settings. MCV is increased, often in the absence of anemia. This finding should not be ignored because it can be an important early clue to reversible disease. For example, it may 1 year or more before
anemia develops in patients with pernicious anemia, and neurologic disease can progress during that interval (Lee, et al.1993). In most surveys, the most common cause of macrocytosis is megaloblastic anemia. In four studies involving 30% to 50% of patients with an increased MCV value were deficient in folate, vitamin B$_{12}$ or both. Nonmegaloblastic anemias were most often associated with alcoholism and liver disease or with hemolytic anemia (Lee, et al.1993). Spurious macrocytosis can result from laboratory artifact. Cold agglutinins, severe hyperglycemia, and marked leukocytosis can lead to incorrect high MCV value (Lee, et al.1993).

1.2.8. **Megaloblastic anemia:**

Megaloblastic anemias are characterized by distinctive cytological and functional abnormalities in peripheral blood and bone marrow cells due to impaired DNA synthesis. They usually result from a deficiency of the B group of vitamins, either vitamin B$_{12}$ or folate (Firkin, et al.1989). Also megaloblastic anemias may arise because abnormal metabolism or because of faults in DNA synthesis not related to cobalamin or folate (Hoffbrand, et al. 1999), but may result from a lesion at some point in pyrimidine or purine synthesis or from inhibition of DNA polymerization (Hoffbrand, et al. 2009).

In temperate zones, pernicious anemia (vitamin B$_{12}$ deficiency), nutritional folate deficiency and folate deficiency due to malabsorption are the most common causes of megaloblastic
anemia. In tropical zones, folate deficiency due to a combination of inadequate intake and malabsorption is the cause of most cases, vitamin B\textsubscript{12} deficiency being less prevalent (Firkin, \textit{et al.} 1989).

\subsection*{1.2.8.1. Pathophysiology of megaloblastic anemia:}

The metabolic pathways of cobalamin and folic acid are complex, however, only a few key reactions are needed to understand megaloblastic anemia. The primary defect is an inability to produce deoxythymidine monophosphate (dTMP) from deoxyuridine monophosphate N, which is catalyzed by the enzyme thymidylate synthetase. 5,10- methylene-tetrahydrofolate (methylene-FH4) is required for the reaction. Cobalamin is involved in the regeneration of methylene FH4 so cobalamin deficiency, in effect, result in folate deficiency. Deoxythymidine monophosphate is converted to deoxythymidine triphosphate (dTTP), which is required for DNA synthesis. In the absence of adequate dTTP, deoxyuridine triphosphate (dUTP) is inserted into DNA, including DNA strand break. Since RNA synthesis unimpaired, cytoplasmic maturation is relatively normal; the cell continuous to synthesize Hb while waiting for DNA synthesis and cell division to be completed, resulting in increased cell size. There is a marked ineffective erythropoiesis, the marrow is markedly hypercellular, but most cells die before leaving the marrow. This result in
massive intramedullary hemolysis and increased levels of serum lactic dehydrogenase (LDH) (Kern, 2002).

Also this deficiency of vitamin B\textsubscript{12} or folate can impair maturation in myelogenous white blood cells and megakaryocytes, producing leucopenia with neutrophilic hypersegmentation and thrompocytopenia. Megakaryocyte fragments and gaillt platelets maybe seen on peripheral blood smears. In addition to hematological manifestations, neuropsychiatric disturbances such as peripheral neuropathy or depression are also common with cobalamin or folate deficiency and may occur in the absence of significant hematological manifestations. These neuropsychiatric conditions are reversible if treated promptly by cobalamin or folate replenishment (Turgeon, 2002).

1.2.8.2. Differentiation from other macrocytic anemia:

In some disorders, macrocytic anemia occurs in association with a normoblastic marrow. These normoblastic anemias are symptomatic anemias secondary to a number of well defined disorders. With most of the disorders a macrocytic anemia is unusual a normocytic anemia being the more common finding. This anemia responds only to alleviation or cure of the underlying disease, and is un inflected by either vitamin B\textsubscript{12} or folic acid therapy.(Kern, 2002)

1.2.8.3. Causes of megaloblastic anemia:
1. Vitamin B\textsubscript{12} deficiency
2. Folate deficiency
3. Abnormalities of vitamin B\textsubscript{12} or folate metabolism e.g. transcobalamin II deficiency, nitrous oxide, and antifolate drugs
4. Other defects of DNA synthesis: congenital enzyme deficiencies e.g. orotic aciduria and acquired enzyme deficiencies, e.g. alcohol therapy with hydroxyurea cytosine arabinoside (Hoffbrand, et al. 2001).

1.2.9. Vitamin B\textsubscript{12} and folate metabolism:
Vitamin B\textsubscript{12} and folate are present in the normal diet of humans and under physiological conditions are absorbed from the gastrointestinal tract in sufficient amount to supply the needs of the body. The general metabolism of these substances is discussed briefly below, as some knowledge is essential to an understanding of the mechanisms causing their deficiency.

**Table (1.2) vitamin B\textsubscript{12} and folate metabolism**
(Firkin, et al. 1989):

<table>
<thead>
<tr>
<th>Content of foods</th>
<th>Vitamin B\textsubscript{12}</th>
<th>Folate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vegetables</td>
<td>Vegeatbles : poor</td>
<td>Vegetables : rich</td>
</tr>
<tr>
<td>Meat</td>
<td>Meat : rich</td>
<td>Meat : moderate</td>
</tr>
<tr>
<td>Effect of cooking</td>
<td>10-30% loss</td>
<td>60-90% loss</td>
</tr>
<tr>
<td>Adult daily requirements</td>
<td>2-4 µg</td>
<td>200 µg</td>
</tr>
<tr>
<td>Adult daily intake</td>
<td>5-30 µg</td>
<td>100-500 µg</td>
</tr>
<tr>
<td>Site of absorption</td>
<td>Ileum</td>
<td>Duodenum and jejunum</td>
</tr>
<tr>
<td>Body stores</td>
<td>2-5mg</td>
<td>5-20mg</td>
</tr>
</tbody>
</table>
1.2.10. Vitamin $B_{12}$:

Vitamin $B_{12}$ occurs naturally in food stuffs. It plays an important role in general cell metabolism acting as a co-enzyme in chemical reactions affecting the synthesis of DNA. In particular, it is essential for normal hemopoiesis and for maintenance of the integrity of the nervous system (Firkin, et al. 1989).

- **Chemistry:**

Vitamin $B_{12}$ was isolated in pure form in 1948 as cyanocobalamin, a red crystalline substance of molecular weight 1355, which belongs to the chemical family of cobalamins (Firkin, et al. 1989).

- **Sources:**

The vitamin $B_{12}$ requirements of humans are obtained from foods mainly those of animal protein origin; kidney, liver and heart are the richest sources, but lesser amount occur in other foods including muscle meats, fish, eggs, cheese and milk. Vegetables contain practically no vitamin $B_{12}$, in contrast to their high content of folate. The principal forms in the diet are adenosylcobalamin and hydroxocobalamin, which are bound to food protein. Vitamin $B_{12}$ is synthesized by micro-organisms and the original source of all vitamin $B_{12}$ in nature is bacterial synthesis. Many of these bacteria are normal in habitants of the gastrointestinal tract, and the faeces normally contain the
vitamin in large amounts. Vitamin B₁₂ is synthesized only in the human large bowel. It is not absorbed from this site, and humans are thus entirely dependent on dietary sources (Firkin, et al. 1989).

- **Absorption:**

  Both active and passive mechanisms exist for the absorption of vitamin B₁₂. The active mechanism is mediated by gastric intrinsic factor and is responsible for the absorption of physiological amounts of vitamin B₁₂ present in food. It is highly efficient: from 60 to 80 % of a 2µg dose of vitamin B₁₂ is absorbed through its operation. When food passes into the stomach, vitamin B₁₂ is released from protein by the action of acid and proteolytic enzymes. In vitro studies by Allen, et al (1978) suggest that the B₁₂ first combines with gastric (R) protein which is mainly derived from saliva and is immunologically identical to the major B₁₂ transport protein, transcobalamin I. as the complex proceeds down the small intestine, the (R) protein is degraded by pancreatic enzymes and the liberated vitamin B₁₂ combines rapidly with intrinsic factor, a glycoprotein of molecular weight 44000 secreted by parietal cells in the fundus and body of the stomach. Normally, the amount of intrinsic factor is far in excess of that needed for B₁₂ absorption; only about 1-2 % of the total output is required under physiological conditions. One molecule of intrinsic factor binds one molecule of vitamin B₁₂ and the attachment stabilizes the latter as it passes into the site of absorption in the distal
small intestine. The intrinsic factor-vitamin B$_{12}$ complex bind to receptors on the brush border of mucosal cells. Progress of the vitamin B$_{12}$ across the mucosal cells is relatively slow. It is not known whether intrinsic factor enters the mucosal cell or remain on the surface. Finally the vitamin B$_{12}$ is released into the portal circulation to bind with transport protein (transcobalamin II , TCII) for distribution to the tissues. The vitamin B$_{12}$ in plasma is mostly methylcobalamin with some adenosylcobalamin and hydroxocobalamin (Firkin, et al. 1989). A second, less efficient, mechanism for absorption operates when the small intestine is presented with supraphysiological doses of vitamin B$_{12}$. No carrier molecule is involved, and passive absorption occurs equally in the jejunum and ileum. One percent of a large oral dose of B$_{12}$ is rapidly absorbed by this mechanism (Hoffbrand, et al. 2006).

- **Transport:**

There are two major vitamin B$_{12}$ binding proteins in plasma, transcobalamin I (TC I) and transcobalamin II (TCII). TC I is an $\alpha_1$-globulin of molecular weight 60000 which carries from 70-90% of the circulating endogenous vitamin B$_{12}$ (mainly methylcobalamin). It appears to function primarily as a storage protein and is not essential for vitamin B$_{12}$ transport. It is synthesized by granulocyte (Firkin, et al. 1989). TC II is a $\beta$-globulin of molecular weight 38,000, which is synthesized in the liver and is essential for the transport of
vitamin $B_{12}$ from one organ to the other and in and out of cells. It is largely unsaturated, binds newly absorbed or injected $B_{12}$, and readily releases the bound vitamin to tissues. Congenital deficiency of TC II leads to a severe megaloblastic anemia. A third plasma binding protein is TC III, which is similar to TC I, bind only a small amount of circulating $B_{12}$ (Firkin, et al. 1989). Measurement of the unsaturated $B_{12}$ binding capacity (UBBC), which in the normal subject reflects the amount of TC II and to lesser extent TC I and TC III available in the serum for binding with added $B_{12}$, may be diagnostically useful in some disease states. The normal range for serum UBBC is 500-1200 ng/l. The UBBC is usually elevated due to an increase in TC I in chronic myeloid leukemia and acute promyelocytic leukemia. In all these conditions, the vitamin $B_{12}$ level is usually increased, but the UBBC correlates with extent of disease more closely than does the $B_{12}$ level (Firkin, et al. 1989).

- **Tissue stores:**
The principle site for storage of vitamin $B_{12}$ is the liver, which contains about 1500 µg. kidneys, heart and brain each contain 20-30 µg. the total body content of vitamin$B_{12}$ ranges from 2 to 5 mg. The storage form is largely adenosylcobalamin (Firkin, et al. 1989).

- **Biological function:**
In spite of the clinical effects of vitamin $B_{12}$ deprivation, its role in the normal metabolism of the human body seems deceptively limited. Only two biochemical reactions in humans
are known with certainty to require vitamin B\textsubscript{12} Co-enzymes: the conversion of methylmalonyle-CoA to succinyl-CoA by adenosylcobalamin and synthesis of methionine from homocysteine by methylcobalamin. The homocysteine-methionine reaction is closely linked with the metabolism of vitamin B\textsubscript{12} is lead to impaired conversion of methyltetrahydrofolate to tetrahydrofolate, which is then not available for DNA synthesis. Vitamin B\textsubscript{12} deficiency, acting through derangement of folate metabolism, causes a clinical picture resembling in some respects that of folate deficiency itself (Firkin, et al. 1989).

1.2.11. Folate:
Folate, one of the water-soluble B vitamins, plays an essential role in cellular metabolism, and is required for a large number of reactions involving transfer of one carbon units from one compound to another (Firkin, et al. 1989).

- **Chemistry:**
Folic acid was synthesized in 1945 as a yellow crystalline powder of molecular weight 441 with the chemical name pteroylglutamic acid (PGA) (Firkin, et al. 1989).

- **Sources:**
Folate is widely distributed in plant and animal tissues. The richest sources are liver, kidney, yeast and fresh green vegetables, especially leafy vegetables such as spinach and cabbage. Lesser amounts are present in other foodstuffs including muscle meat, some fruit, and cereals. Milk has a
moderately low folate content. Some folate is synthesized by bacteria in large intestine. (Firkin, et al. 1989)

- **Absorption:**
Folate is normally absorbed from the duodenum and upper jejunum, and to lesser extent from the lower jejunum and ileum. Absorption of synthetic folic acid is a rapid active process: 80 per cent of a physiological dose is absorbed unchanged, with a peak serum level one hour after oral administration. Food folate monoglutamates are also readily absorbed, but the absorption of food polyglutamates is variable. Synthetic polyglutamates are absorbed almost as well as monoglutamates, but the presence of availability from some foodstuffs. Polyglutamates are cleaved to the monoglutamate form by the enzyme pteroylpolyglutamate conjugase with in the mucosal cell. Most monoglutamates undergo further reduction and methylation in the mucosa, emerging into the circulation as methyltetrahydrofolate (Firkin, et al. 1989).

- **Transport:**
Folates circulate in plasma as methyltetrahydrofolate monoglutamate, either in the free form or weakly bound to a variety of proteins. A specific high-affinity folate binding protein may account for a small proportion of binding capacity of plasma (Firkin, et al. 1989).

- **Tissue stores:**
Folates are mainly stored in the liver in the polyglutamate form. Liver and red cell folate is largely methyltetrahydrofolate
polyglutamate. The total body content is 5-20 mg, and stores are exhausted in about four months if intake totally ceases. Normal loss occurs from sweat, saliva, urine and faeces (Firkin, et al. 1989).

- **Biological function:**
Folate co-enzymes are required for several biochemical reactions in the body involving:

- Transfer of one-carbon units from one compound to another.
- Methylolation of homocysteine to methionine.
- Synthesis of the pyrimidine nucleotide, thymidylate monophosphate from deoxyuridylate monophosphate in the DNA synthesis pathway.(Firkin, et al. 1989)

The vitamin B\textsubscript{12}-dependent homocysteine-methionine reaction is important in the generation of tetrahydrofolate from methyltetahydrofolate. The synthesis of thymidylate from deoxyuridylate is a critical rate-limiting step in DNA synthesis and requires methylenetetrahydrofolate (Firkin, et al. 1989).

1.2.12. Causes of cobalamin (B\textsubscript{12}) and folate deficiency:

1.2.12.1. Causes of cobalamin (B\textsubscript{12}) deficiency:

1. Malabsorption
2. Gastrectomy: loss of IF production and gastric acid
3. Disorders of alimentary tract: produce lack of intrinsic factor, impairment of the absorptive capacity of the
intestinal mucosa, and interference with normal absorption by bacteria or parasites.

4. Resection of terminal ileum: loss of absorption by specific IF-B$_{12}$ receptor.

5. drugs and chronic pancreatic disease: inability to digest R-binder of B$_{12}$ (Kern, 2002).

6. Increase utilization of vitamin B$_{12}$ because of parasitic infections such as fish tape worm and pathogenic bacteria (Turgeon, 2002). The most common cause of cobalamin deficiency is pernicious anemia which is an autoimmune chronic gastritis, resulting in destruction of the parietal cell and loss of IF production. It occurs in all ethnic group, although the highest incidence appears to be in person of Scandinavian, English, Scottish, and Irish descent. In Caucasians the average age onset is about 60 years, although it can be seen at all ages including children (Kern, 2002) patient with pernicious anemia have an increased risk of gastric carcinoma compared to the general population. The increase in the risk is significant, but the over all risk for individual patient is low (Kern, 2002)

1.2.12.2. Causes of folate deficiency:
Most causes of folate deficiency are due to inadequate diet, chronic alcoholics which are particular risk for folate deficiency because they are less likely to eat fresh fruits and vegetables
and because alcohol interferes with folate metabolism. (Kern, 2002)

• **Common causes:**
  - inadequate diet
  - Alcoholism
  - Lack of fresh fruit and vegetables
  - Malabsorption
  - Gluten-sensitive enteropathy
  - Tropical sprue
  - Extensive small bowel resection
  - Inflammatory bowel disease. (Kern, 2002)
  - Increase utilization caused by pregnancy or some acute leukemias (Turggeon, 2002)

• **Rare causes:**
  - Hemodialysis
  - Antipiliptic drugs
  - Anti folate drugs
  - oral contraceptives
  - Exposure to nitrous oxide ($N_2O$). (Kern, 2002)

**1.2.13. General tissue effects of cobalamin and folate deficiencies:**
These deficiencies, when severe, affect all rapidly growing (DNA-synthesizing) tissues. After the marrow, the next most affected tissues are epithelial cell surfaces of the mouth, stomach and the small intestine, and the respiratory, urinary
and female genital tracts. The cells show macrocytosis, with increased numbers of multinucleate and dying cells (Hoffbrand, et al. 1999).

1.2.14. Symptoms and signs of megaloblastic anemia:
Many patients are detected by routine blood counts, because of a raised mean corpuscular volume (MCV). The main symptoms and signs in more severe cases are those of anemia (Hoffbrand, et al. 1999)

Table (1.3) symptoms and signs of megaloblastic anemia (Kern, 2002):

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weakness, tiredness, weight loss</td>
<td>Pallor skin</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>Dry, smooth (velvety) skin</td>
</tr>
<tr>
<td>Painful tongue and mouth</td>
<td>Smooth, red (beefy) tongue</td>
</tr>
<tr>
<td>Loss of appetite, nausea, vomiting</td>
<td>Silver coloration or premature graying of hair.</td>
</tr>
</tbody>
</table>

1.2.15. Laboratory evaluation of megaloblastic anemia:
The CBC shows anemia, which can be quite striking. The MCV is increased (often ≥ 120 fl) (Frances, 2000).

1.2.15.1. Laboratory abnormalities:
- Decrease Hb level
- Increase MCV
- Oval macrocytes
- Leukopenia
- Hypersegmented neutrophils
- Thrombocytopenia
- Increase lactic dehydrogenase (LD) enzyme
- Increase bilirubin
- Decrease haptoglobin (Dacie and Lewis, 2001)

### 1.2.15.2. Peripheral blood picture in megaloblastic anemia:

On blood smear, erythrocytes show both macrocytosis and ovalocytosis, the presence of oval macrocytes is very suggestive of megaloblastic anemia. In severe cases, there may be teardrop and fragmented RBCs, Howell-Jolly bodies, and nucleated RBCs. The characteristic finding in granulocytes is hypersegmented neutrophils. Hypersegmented neutrophils are defined by the rule of fives. Either more than five distinct nuclear lobes in any cell or \( \geq 5\% \) of neutrophils have five distinct nuclear lobes (Frances, 2000)

Hypersegmented neutrophils: are one of the earliest blood findings of megaloblastic anemia and may precede both anemia macrocytosis. They are also one of the last morphologic changes to disappear after therapy is started (several days to 2 weeks). The presence of hypersegmented neutrophils in patient...
with a macrocytic anemia is strong indication that process is megaloblastic anemia (Dacie and Lewis, 2001).

![Peripheral blood smear showing hypersegmented neutrophil, characteristic of megaloblastic anemia.](image)

**Figure (1.1) Peripheral blood smear showing hypersegmented neutrophil, characteristic of megaloblastic anemia.**

**1.2.15.3. Bone marrow picture in megaloblastic anemia:**
- Megaloblast (enlarged erythrocyte precursors with immature nuclear chromatin)
- Giant bands and metamyelocyte (Dacie and Lewis, 2001).
Figure (1.2) bone marrow smear showing megaloblast cells

The marked intramedullary hemolysis results in an increase in serum lactic dehydrogenase (LD or LDH) and bilirubin and a decrease in serum haptoglobin. The LD is often several thousand international units. (Kern, 2002)

1.2.15.4. Special tests:

- Serum cobalamin, serum folate, and erythrocyte folate levels will establish the cause of megaloblastic anemia in most cases.
- The serum folate level is labile and may easily fluctuate with meals. Therefore, if a patient with folate deficiency is admitted to the hospital and the blood sample is drawn after a couple of good meals, then the serum folate level may be normal. The erythrocyte folate level, on the other hand, is likely to remain depressed for several days (Dacie and Lewis, 2001).
- Two additional tests that may be useful are serum levels of methylmalonic acid (MMA) and homocysteine. An increase in MMA is very sensitive for cobalamin deficiency and may be clearly increase when the serum cobalamin is borderline and before the hemoglobin begins to decrease. Both the MMA and homocysteine levels are increased in cobalamin deficiency. In folate deficiency, homocysteine is characteristically increased, whereas the MMA is usually normal (Dacie and Lewis, 2001).

Table (1.4) Abnormalities tests associated with megaloblastic anemia (Frances, 2000):

<table>
<thead>
<tr>
<th>Name of test</th>
<th>Cobalamin</th>
<th>Folate</th>
</tr>
</thead>
</table>

31
<table>
<thead>
<tr>
<th></th>
<th>deficiency</th>
<th>deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. cobalamin</td>
<td>Decreased</td>
<td>Usually normal</td>
</tr>
<tr>
<td>S. folate</td>
<td>Normal to increase</td>
<td>Decreased</td>
</tr>
<tr>
<td>Erythrocyte folate</td>
<td>Decreased</td>
<td>Decreased</td>
</tr>
<tr>
<td>S. methylmalonic acid</td>
<td>Increased</td>
<td>Normal</td>
</tr>
<tr>
<td>S. homocysteine</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(moderately)</td>
</tr>
</tbody>
</table>

**1.2.16. Pernicious anemia:**

This is caused by autoimmune attack on the gastric mucosa leading to atrophy of the stomach. The wall of the stomach becomes thin with a plasma cell and lymphoid infiltrate of the lamina propria. Intestinal metaplasia may occur. There is achlorhydria and secretion of IF is absent or almost absent. Serum gastrin levels are raised. Helicobacter pylori infection may initiate an autoimmune gastritis which presents in younger subject as iron deficiency and in the elderly as pernicious anemia (Hoffbrand and Moss, 2010).

**1.2.16.1. Antibodies:**

Ninety per cent of patients show parietal cell antibody in the serum directed against gastric H\(^+\)/K\(^+\)-ATPase, and 50% type I or blocking antibody to IF which inhibits IF binding to B\(_{12}\). Thirty-five per cent show a second (type II or precipitating) antibody to IF which inhibits its ileal blinding site (Hoffbrand and Moss, 2010).

**1.2.16.2. Epidemiology:**
Research studies have recently documented that 1.9% of persons older than 60 years have undiagnosed pernicious anemia. Earlier studies suggested that pernicious anemia is restricted to Northern Europeans; however, newer studies report the disease in both blacks and Latin Americans. The median age at diagnosis is 60 years. Slightly more women than men are affected (Turgeon, 2002).

1.2.16.3. Schilling Test:
The standard method to diagnose pernicious anemia, once cobalamin deficiency is confirmed, is the Schilling test. Radiolabeled cobalamin is given orally, a large dose of unlabeled $\text{B}_{12}$ is given intramuscularly, and urine is collected for 24 hours. The amount of radioactivity in the urine indicates how much $\text{B}_{12}$ was absorbed orally. Typically, recovery of < 6% in the urine indicates malabsorption of $\text{B}_{12}$. If the initial value is abnormal, a second stage is performed in which intrinsic factor is given together with the labeled $\text{B}_{12}$. An increase in the amount of $\text{B}_{12}$ absorbed during the second stage of the Schilling test indicates pernicious anemia. (The purpose of the intramuscular $\text{B}_{12}$ is saturate the $\text{B}_{12}$-binding sites in the serum, and there by flush all of the orally absorbed $\text{B}_{12}$ in to the urine, where it can be measured. (Kern , 2002)

-The Schilling test can be done even if the patient has been on $\text{B}_{12}$ therapy for months or years. Cobalamin therapy will correct the hematologic complications of pernicious anemia but will not
correct the gastric atrophy or the lack of IF production. (Kern, 2002)

-The schilling test is done to investigate the cause of cobalamin deficiency, there is no reason to do a schilling test in patient with folate deficiency. (Kern, 2002).

-Some experts believe that there is no reason to do a schilling test in cobalamin deficiency, they presume that pernicious anemia is the most likely diagnosis, and treatment of cobalamin deficiency of any cause is the same. Assay of serum anti-parietal cell or anti-IF antibodies can be useful in diagnosis of pernicious anemia. (Kern, 2002).

**1.2.17. Nonmegaloblastic anemia:**

Several mechanism may cause nonmegaloblastic macrocytosis:

- **Accelerated Erythropoiesis:** Mild to moderate macrocytosis often follows erythropoietin-mediated acceleration of red cell production as may be induced by blood loss or hemolysis. Disorders associated with it are hemolytic anemia and posthemorrhagic anemia.

- **Thin macrocytes:** defined as cells with increased surface area but without a corresponding increase in volume. Disorders associated with it, are hepatic disease, obstructive jaundice and postsplenectomy.

- **Refractory anemia:** the macrocytosis that accompanies various refractory anemias, including myelodisplastic anemias, Aplastic anemia, Aquired sidroblastic anemia and idiopathic macrocytosis in the elderly.
• Alcoholism: macrocytosis, usually mild, many of whom have no anemia. The finding is so characteristic of the condition that testing for macrocytosis has been used as part of screening procedure for the early detection of alcoholism. (Lee, et al. 1998)

1.2.18. Previous studies:
There were many studies done in megaloblastic in children in different countries, from these studies:
Study done by Dr. Tariq Ayub and Dr. Fezal Ur Rahman Khan in Pakistan in 2008, this study done in 40 childern with age range(0-12)years, they found that 23(57.5%) have megaloblastic anemia.

1.3. Rationale:
Megaloblastic anemia is considered as a public health problem and almost common nutritional deficiency around the world, because it affects development, growth, and impaired learning
process. The incidence data of megaloblastic anemia Among children is rare and different from country to country due to nutrition. This study is very important because there is little data base information about megaloblastic anemia in sudan.

1.4. Objectives:

1.4.1. General objectives:
To find out the frequency of megaloblastic anemia among children with macrocytic anemia referred to Gaafer Ibn Auf hospital (pediatric hospital)

1.4.2. Specific objectives:
1- To measure blood parameters, which include Hb level, RBCs count, WBCs count, PCV, Plts count, MCV, MCH, and MCHC of children.
2- To assess morphology of red blood cells.
3- To know the affect of age and sex to megaloblastic anemia.
4- To determine the frequency of anemia, leucopenia, thrombocytopenia, and pancytopenia among study group.
Chapter two

2- Materials and Methods

2.1. Study approach:
This study was conducted to find out the frequency of megaloblastic anemia among children with macrocytic anemia in Gaafer Ibn Auf Hospital through the period between March and June 2015.

2.2. Study design:
This study was a descriptive, cross sectional analytical study.

2.3. Study area:
This study was conducted at Gaafer Ibn Auf Hospital.

2.4. Sample size:
Fourty EDTA venous blood samples were collected from children with macrocytic anemia referred to Gaafer Ibn Auf hospital.

2.5. Tools of data collection:
EDTA anticoagulant blood sample was used to evaluate the blood cell count, stained film to determine morphology of cells, also a questionnaire was used to obtain the demographic data about the test group . Bone marrow aspirate was performed to confirm diagnosis.

2.6. Selection criteria:

2.6.1. Inclusion criteria:
Children with MCV more than 100 fl and Hb less than 10 g/dl.

2.6.2. Exclusion criteria:
Children with MCV less than 100 fl and Hb more than 10 g/dl.

2.7. Ethical consideration:
Children parent·s were informed in their simple language about the research and its benefits, method of sample collection, and the approval consent was taken, the data was kept in highly security mode, also the Hospital administration was informed and the written approval was taken.

2.8. Method of sample collection:
2.8.1. Requirements:
1. K²EDTA containers
2. Cotton
3. Alcohol (70% ethanol)
4. Syringes
5. Tourniquet

2.8.2. Procedure:
1. Patient was sat down right on an examination table
2. The arm was positioned on the arm rest so that the vein identified become under some tension and its mobility was reduced.
3. The skin was cleaned with 70% ethanol and allow to dry, to avoid staining when the skin is penetrated.
4. Personal details were checked up on the forms and blood vials.
5. A tourniquet was applied to the arm, light sufficiently to distend the vein, but not tightly to cause discomfort.

6. 2.5 ml of blood samples were taken from the superficial vein of the forearm.

7. Blood was collected in K²EDTA anticoagulant and mixed gently then labeled with patient’s name, date, and patient’s number (Dacie and Lewis, 2006) K²EDTA blood samples were analyzed for CBC by sysmex 21 and prepared thin film for morphology.

2.9. Complete blood count:
Evaluation of the blood counts, were performed by sysmex automated hematological analyzer which could perform 18 hematological parameters with high accuracy and precision. Principally sysmex analyzer is based on the electronic resistance (impedance) detection method for counting and sizing recognition of leukocyte, erythrocyte and platelet. Through using three preliminary hydraulic systems for WBCs, RBCs, platelet and hemoglobin, and display the mode of blood cells count result on the liquid crystal displayer (LCD) with histogram and printed out results in thermal paper (Dacie and Lewis, 2006).

2.9.1. Principle of sysmex 21 hematological analyzer:
Measurement of blood cells (RBC’s, WBC’s, and platelet ) and hemoglobin concentration obtained by aspiration of small volume of well mixed (K²EDTA) blood by sample probe and
mixed with isotonic diluents in nublazer. Diluent aspiration delivered to RBC’s aperture bath for providing information about RBC’s and platelet. Other portion of aspirated sample induced in to WBC’s bath in which hemolytic reagent (stromatolyzer) added to break down RBC’s and release of hemoglobin which measured in bulid colorimeter based on cyanomet hemoglobin method (HICN). The through three sensing apertures for each cell type, cells counted and size information generated in triplicate pulses acting to electronic conductivity. Mentioned pulses converts in to digital number using in bulid calculator programmed and designed for RBC’s and WBC’s counts. Some portion of diluted sample delivered to in bulid hemoglobin meter at the same time, hence three values directly measured (RBC’s, TWBC’s, Hb) And displayed on (LCD). Other values of red cell indices, leukocyte differential and absolute count calculated from given information, the result printed out aced to the setting mode. On the other hand platelet count and histogram determind from pulses acting to the platelet (Dacie and Lewis, 2006) Reagents and materials provided by sysmex manufacture and contain:

1. Sample: well mixed K²EDTA blood
2. Cell back
3. Stromatolyzer
4. Detergent
5. Cell cleaner
2.9.2. Procedure of sysmex 21:
1. The reagent needed was checked and the power switch was turned.
2. Self auto rinse, and back ground check was automatically performed and the vend (vend for analysis) will appear.
3. Whole blood mode was selected.
4. Sample number and patient name were entered.
5. Sample was mixed sufficiently.
6. The tube was set to the sample probe, and in that condition the start switch was pressed.
7. When the sucking of the sample was done, the tube was removed.
8. After that automatic analysis was done and the result was displayed in the screen. (Orphee, 2004)

2.10. Thin blood film:

2.10.1. Preparation of thin blood film:

- **Equipments:**
  - Slides
  - Spreaders
  - Blood sample

- **Procedure:**
  A small drop of blood was placed in the centre line of a slide about 1 cm from one end. Then, without delay, the spreader was placed in front of the drop at an angle of about 30° to the slide and was moved back to make contact with drop. The drop of blood was spread quickly along the line of contact. With a
steady movement of the hand, the drop of blood was spread along the slide, the spreader did not lift off until the last trace of blood was spread out, with a correctly sized drop; the film was about 3 cm in length. The film was dried by air then stained. (Orphee, 2004)

2.10.2. Staining of thin blood film:

- **Equipments:**
  - Thin blood film
  - Staining rack
  - Leishman’s stain
  - Buffer (tap water)

- **Procedure:**
  The film was placed on the staining rack then flooded by the stain for two minutes. Then the buffer was applied for additional eight minutes. After that the slide was washed well by the buffer and let to dry by air. The film was examined under the microscope (100 lenses) (Lewis, et al. 2006).

2.11. Bone marrow aspiration:

Bone marrow aspiration was performed by a physician and obtained by needle. A small aspiration of marrow was generally representative of the entire bone marrow. Smalls of aspirated marrow were prepared immediately as smear on glass slide after the specimen was obtained. Then dry and stained by leishman’s stain to determine morphology of cells to confirm diagnosis (Barbara, 1993).

**Chapter three**
3- Results

3.1. Demographic data and clinical history of study group:
Table (3-1) shows the frequency of male was 15(37.5%) and 25(62.5) were female. The frequency of age range from (5-8) years was 20(50%) and 20(50%) were age range from (9-12) years. The frequency of anemia diagnosed was 36(90%) and 4(10%) were non anemia diagnosed previously. childern took treatment for anemia were 36(90%) those who have not taken treatment for anemia were 4(10%). Blood transfused children were 20(50%) and others have not transfused with blood were 20(50%). Children of family with and without history of anemia were 28(70%) and 12(30%) respectively. On the basis of nutritional status, children of good nutritional status were 22(55%) and of bad nutritional status were 18(45%), and according to economic status, children of good economical status were 35(87.5%) and of bad economical status were 5(12.5%).

Table (3-1) Demographic data and clinical history of study group:

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Frequency</th>
<th>Percentage %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>15</td>
<td>37.5</td>
</tr>
<tr>
<td>Female</td>
<td>25</td>
<td>62.5</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age Range</td>
<td>36-50</td>
<td>4-10</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------</td>
<td>------</td>
</tr>
<tr>
<td>5-8 years</td>
<td>20</td>
<td>50</td>
</tr>
<tr>
<td>9-12 years</td>
<td>20</td>
<td>50</td>
</tr>
</tbody>
</table>

**Anemia diagnosed previously**

- **Yes**: 36, 90
- **No**: 4, 10

**Treatment of anemia**

- **Yes**: 36, 90
- **No**: 4, 10

**History of Blood transfusion**

- **Yes**: 20, 50
- **No**: 20, 50

**Family history of anemia**

- **Yes**: 28, 70
- **No**: 12, 30

**Nutritional status**

- **Bad**: 18, 45
- **Good**: 22, 55
- **Excellent**: 0, 0

**Economical status**

- 45
### Table (3-2) mean of Hb, RBCs count, TWBCs, Plt, PCV, and red cell indices in study group:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean</th>
<th>Std.deviation</th>
<th>Normal Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>TWBCs ×10³/µl</td>
<td>9.7</td>
<td>6.2</td>
<td>4-7</td>
</tr>
<tr>
<td>TRBCs×10⁶/µl</td>
<td>2.01</td>
<td>0.5</td>
<td>4.5-5.5</td>
</tr>
</tbody>
</table>

#### 3.2. Results of Hb, RBCs count, PCV, red cell indices, TWBCs, Plt count in study group:

Table (3-2) shows the mean of Hb g/dl, TRBCs×10⁶/µl, and PCV % were 6.9±SD, 2.01±SD, and 21.5±SD respectively. MCV fl, MCH pg, MCHC % were 107.3±SD, 34.1±SD, 31.8±SD, and TWBCs×10³/µl, Plt×10³/µl were 9.7±SD, 274±SD in study group.
### 3.3. Blood count findings in study group:

Table (3-3) shows the frequency of anemia, leucopenia, thrombocytopenia, and pancytopenia were 40(100%), 8(20%), 9(22.5%) and 6(15%) in study group.

**Table (3-3) blood count findings in study group:**

<table>
<thead>
<tr>
<th></th>
<th>Anemia</th>
<th>Leukopenia</th>
<th>Thrombocytopenia</th>
<th>Pancytopenia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases</td>
<td>40</td>
<td>8</td>
<td>9</td>
<td>6</td>
</tr>
<tr>
<td>Percentage</td>
<td>100%</td>
<td>20%</td>
<td>22.5%</td>
<td>15%</td>
</tr>
</tbody>
</table>

### 3.4. Frequency of blood film and bone marrow picture in study group:

Table (3-4) shows that the frequency of oval macrocytosis with hypersegmented neutrophil in film and megaloblast in marrow was 3(7.5%), macrocytosis with sickle shape in film was
27(67.5%), and macrocytosis in film and hypoplasia/aplasia in marrow was 10(25%).

**Table (3-4) Frequency of blood film and Bone marrow picture in study group:**

<table>
<thead>
<tr>
<th>Picture</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oval macrocytosis with hypersegmented neutrophil in film and megaloblast in marrow</td>
<td>3</td>
<td>7.5</td>
</tr>
<tr>
<td>Macrocytosis with sickle shape in film</td>
<td>27</td>
<td>67.5</td>
</tr>
<tr>
<td>Macrocytosis in film and hypoplasia/aplasia in marrow</td>
<td>10</td>
<td>25</td>
</tr>
</tbody>
</table>

**3.5. Frequency of megaloblastic anemia in study group:**

Table (3-5) shows that the frequency of megaloblastic anemia was 3(7.5%) and non megaloblastic anemia was 37(92.5%) in study group.

**Table (3-5) Frequency of megaloblastic anemia in study group:**

<table>
<thead>
<tr>
<th>Anemia</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Megaloblastic anemia</td>
<td>3</td>
<td>7.5</td>
</tr>
<tr>
<td>Nonmegaloblastic anemia</td>
<td>37</td>
<td>92.5</td>
</tr>
</tbody>
</table>
3.6. Results of Hb, RBCs count, red cell indices, TWBCs and plt count in children with megaloblastic anemia compared with children of non megaloblastic anemia in study group:

Table (3-6) shows the mean of Hb, RBCs, and PCV were 6.5 g/dl±SD, 1.7×10⁶/µl±SD, and 20.5%±SD for megaloblastic anemia, were no difference in comparing with non megaloblastic anemia (P.value >0.05). the mean of MCV, MCH were 123.8fl±SD, 39.4pg±SD for megaloblastic anemia, were higher significant difference in comparing with non megaloblastic anemia (P.value<0.05). the mean of MCHC, TWBCs, Plt were 31.7%±SD, 7.7×10³/µl±SD, 186×10³/µl±SD for megaloblastic anemia, were no difference in comparing with non megaloblastic anemia in study group.

**Table (3-6) Results of Hb, RBCs count, red cell indices, TWBCs and Plt count in children with megaloblastic anemia compared with children of non megaloblastic anemia in study group:**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Anemia</th>
<th>No</th>
<th>mean</th>
<th>Std.deviation</th>
<th>P.value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb g/dl</td>
<td>Megaloblastic</td>
<td>3</td>
<td>6.5</td>
<td>2.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nonmegaloblastic</td>
<td>37</td>
<td>6.9</td>
<td>1.8</td>
<td>0.712</td>
</tr>
<tr>
<td>Hb%</td>
<td>Megaloblastic</td>
<td>3</td>
<td>44</td>
<td>18.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nonmegaloblastic</td>
<td>37</td>
<td>47</td>
<td>12.4</td>
<td>0.718</td>
</tr>
<tr>
<td>Parameter</td>
<td>Megaloblastic</td>
<td>Nonmegaloblastic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------</td>
<td>------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRBCs×10⁶/µl</td>
<td>3 1.7 0.7</td>
<td>37 2.04 0.5 0.249</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV%</td>
<td>3 20.5 8.9</td>
<td>37 21.6 5.5 0.768</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCV fl</td>
<td>3 123.8 1.1</td>
<td>37 106 4.3 0.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCH pg</td>
<td>3 39.4 2.2</td>
<td>37 33.6 1.9 0.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCHC %</td>
<td>3 31.7 1.7</td>
<td>37 31.8 1.4 0.932</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TWBCs×10³/µl</td>
<td>3 7.7 5.0</td>
<td>37 9.9 6.3 0.553</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plt×10³/µl</td>
<td>3 186 182.2</td>
<td>37 281 182.4 0.389</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
3.7. Frequency of anemias related to sex in study group:
Table (3-7) shows accordingly to sex the frequency of megaloblastic anemia in male was 2(5.0%) and in female was 1(2.5%), and the frequency of nonmegaloblastic anemia in male and female were 13(32.5%) and 24(60%) respectively.

Table (3-7) Frequency of anemia related to sex in study group:

<table>
<thead>
<tr>
<th>Sex</th>
<th>Anemia</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Megaloblastic</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>2</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>5.0%</td>
<td>32.5%</td>
</tr>
<tr>
<td>Female</td>
<td>1</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>2.5%</td>
<td>60%</td>
</tr>
<tr>
<td>Total</td>
<td>3</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>7.5%</td>
<td>92.5%</td>
</tr>
</tbody>
</table>

P.value: 0.278

3.8. Frequency of anemias related to age in study group:
Table (3-8) shows accordingly to age group, the frequency of megaloblastic anemia in age range (5-8) years was 2(5.0%) and in age range (9-12) years was 1(2.5%), and for
nonmegaloblastic anemia, the frequency was 18(45%) in age range (5-8) years and 19(47.5%) in age range (9-12) years.

**Table (3-8) Frequency of anemias related to age in study group:**

<table>
<thead>
<tr>
<th>Age range</th>
<th>Anemia</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Megaloblastic</td>
<td>Nonmegaloblastic</td>
</tr>
<tr>
<td>(5-8) years</td>
<td>2</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>5.0%</td>
<td>45%</td>
</tr>
<tr>
<td>(9-12) years</td>
<td>1</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>2.5%</td>
<td>47.5%</td>
</tr>
<tr>
<td>Total</td>
<td>3</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>7.5%</td>
<td>92.5%</td>
</tr>
</tbody>
</table>

P.value: 0.548
Chapter four

Discussion, Conclusion, and Recommendations

4.1. Discussion:

This study was a descriptive and analytic study that aimed to determine the frequency of megaloblastic anemia in children with macrocytic anemia in Gaafer Ibn Auf hospital in Khartoum state.

Fourty samples were collected from children in Gaafer Ibn Auf hospital (pediatric hospital), through the period from March 2015 to June 2015, their age was range from (5-12) years, 15 samples were males and 25 samples were females. The full blood count (TWBCs, TRBCs, Hb, PCV, MCV, MCH, MCHC, Plts) was performed immediately by using automation method. Stained blood films were performed to determine morphology
of red cells and bone marrow aspirates were used to confirm diagnosis. Then the data analyzed by SPSS computer program. In this study, the mean of TWBCs was $9.7 \times 10^3 \pm 6.2$ cell/µl and the reference range is $(4-7) \times 10^3$cell/µl. The mean of RBCS count was $2.01 \times 10^6 \pm 0.5$cell/µl and the reference range is $(4.5-5.5) \times 10^6$cell/µl. The mean of Hb was $6.9 \pm 1.9$ g/dl, $47 \pm 12.6$ % and the reference range is $(10.3-15)$g/dl , $(70-100)$% respectively. The mean of PCV was $21.5 \pm 5.8$ % and the reference range is $(38-54)$% . The mean of MCV was $107.3 \pm 6.3$ fl and the reference range is $(80-100)$fl. The mean of MCH was $34.1 \pm 2.5$ pg and the reference range is $(27-32)$pg. The mean of MCHC was $31.8 \pm 1.4$ % and the reference range is $(32-36)$%. The mean of Plt was $274 \times 10^3 \pm 181.8$cell/µl and the reference range is $(150-450) \times 10^3$cell/µl.

According to results of CBC, Blood film, and Bone marrow aspirate, the anemia in this study group was classified in two anemias which were megaloblastic anemia and nonmegaloblastic anemia. The hematological parameters of megaloblastic anemia were compared with nonmegaloblastic anemia. The mean of Hb g/dl, RBCs$\times 10^6$/µl, PCV in megaloblastic group were $6.5 \pm 2.7$, $1.7 \pm 0.7$, $20.5 \pm 8.9$, and in nonmegaloblastic group were $6.9 \pm 1.8$, $2.04 \pm 0.5$, $21.6 \pm 5.5$ with no significant difference found that $P$.value $> 0.05$

The mean of MCV fl, MCH pg in megaloblastic group were $123.8 \pm 1.1$, $39.4 \pm 2.2$, and in nonmegaloblastic group were
106±4.3, 33.6±1.9 with higher significant difference found that P.value <0.05.
The mean of MCHC%, TWBCs×10³/µl, Plt×10³/µl in megaloblastic group were 31.7±1.7, 7.7±5.0, 186±182.2 and in nonmegaloblastic anemia were 31.8±1.4, 9.9±6.3, 281±182.4 with no significant difference found that P.value >0.05.
In comparing between sex, age and megaloblastic anemia, there was no difference found that P.value >0.05.
There were many previous studies that were done to evaluate the prevalence of megaloblastic anemia in infant. For example: study done by Tariq Ayub and Fazal Ur Rahman Khan in Pakistan. This study was a retrospective analysis of forty bone marrow aspirates was performed to find out the prevalence of megaloblastic anemia in paediatric unit of district Head quarter teaching Hospital from January 2007 to December 2008. Both male and female indoor patients up to 12 years of age were included in the study. The result of this study was blood count and peripheral smear findings revealed anemia in 40 (100%) which agreed with my study.
In study done by Dr. Tariq, et al, also revealed leucopenia in 17 (42.5%), thrombocytopenia in 36 (90%), and pancytopenia in 17 (42.5%) patients which did not agree with my study, because it revealed leucopenia in 8 (20%), thrombocytopenia in 9 (22.5%), pancytopenia in 6 (15%) and the peripheral smears also showed sickle shape in 27 (67.5%) patients.
In study done by Dr. Tariq, et al 2008 in Pakistan; the analysis of bone marrow findings showed megaloblastic anemia in 23 (57.5%), bone marrow hypoplasia/aplasia in 8 (20%), leukemia in 6 (15%), and miscellaneous in 3 (7.5%) patients. So megaloblastic anemia was the most common finding in this study which did not agree with my study, because the bone marrow findings showed megaloblastic anemia in 3 (7.5%), bone marrow hypoplasia/aplasia in 10 (25%), and miscellaneous in 27 (67.5%) patients. So megaloblastic anemia was less common among this study population.
4.2 Conclusion:
This study concluded:
1- 3(7.5%) samples were megaloblastic anemia while 37(92.5%) samples were nonmegaloblastic anemia, according to results of CBC, blood film, and marrow aspirates.
2- The megaloblastic anemia was less frequent among this study population.
3- There was significant difference in comparing of MCV, MCH, between megaloblastic and nonmegaloblastic anemia.
4- There was no difference between sex, age, and megaloblastic anemia.
4.3 Recommendations:

- Serum $B_{12}$ and serum folic acid tests must be done to determine causes of megaloblastic anemia.

- Encourage mothers to take vitamin during pregnancy.

- Encouragement of periodic medical check up to avoid the complication of megaloblastic anemia.

- Education program for the mothers to know more about healthy and benefited food for their children.

- Samples size should be increase for more reliable result.

- Medical counseling for early detection of megaloblastic anemia is required.
References:


• **Hoffbrand, A. V., Lewis, S. M. and Tuddenham, (2004)**

• **Hoffbrand, A. V., Pettit, J. E. and Paresh, V. Y. (2009)**


  Hematology an Illustrated colour text. 3rd edition. Philadelphia, USA: Churchill livingstone Elservier.

• **Kern William, F. (2002)**

• **Lee, G. R., Foerster John, Lukens John et al. (1998)**


Appendices
Appendix (1)

بسم الله الرحمن الرحيم

جامعة السودان للعلوم والتكنولوجيا

برنامج ماجستير علوم المختبرات الطبية (تخصص علم الدم

بحث تكميلي لنيل درجة الماجستير

موضوع البحث: فقر الدم الضخم الروماتي لدى الأطفال في مستشفى جعفر بن عوف

الهدف من البحث:

الكشف عن فقر الدم الضخم الأوروماتي ومضاعفاته بما لديه من معوقات جسمية وعقلية عند الأطفال في الفئة العمرية من 5 الى 12 سنة ويتطلب البحث أخذ عينة مقدارها 2.5 مل وهذا البحث لن يتطلب تجارب غير أخلاقية.

الاستبيان:

الاسم......................................................... العمر........................................

هل لدى الأسرة أمراض نقص الدم؟

الوضع الاقتصادي: ممتاز... جيد... ضعيف

الوضع الغذائي: ممتاز... جيد... ضعيف

هل لديك أنيمياء من قبل؟

هل تأخذ علاج للأنيمياء؟

هل أجري لك نقل دم؟

Appendix(2) plates:
Microscope
Figure show frequency of megaloblastic anemia in study group
Sysmex 21
## Appendix(3) master sheets:

<table>
<thead>
<tr>
<th>No</th>
<th>Sex</th>
<th>Age years</th>
<th>Anemia diagnosed</th>
<th>Treatment of anemia</th>
<th>Blood transfusion</th>
<th>Family history of anemia</th>
<th>Nutritional status</th>
<th>Economic status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Female</td>
<td>6</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Bad</td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td>9</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Good</td>
</tr>
<tr>
<td>3</td>
<td>Female</td>
<td>11</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Good</td>
</tr>
<tr>
<td>4</td>
<td>Male</td>
<td>12</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Good</td>
</tr>
<tr>
<td>5</td>
<td>Male</td>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Bad</td>
</tr>
<tr>
<td>6</td>
<td>Male</td>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Good</td>
</tr>
<tr>
<td>7</td>
<td>Female</td>
<td>9</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Good</td>
</tr>
<tr>
<td>8</td>
<td>Male</td>
<td>6</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Good</td>
</tr>
<tr>
<td>9</td>
<td>Male</td>
<td>6</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Good</td>
</tr>
<tr>
<td>10</td>
<td>Female</td>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Good</td>
</tr>
<tr>
<td>11</td>
<td>Female</td>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Good</td>
</tr>
<tr>
<td>12</td>
<td>Male</td>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Bad</td>
</tr>
<tr>
<td>13</td>
<td>Female</td>
<td>7</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Bad</td>
</tr>
<tr>
<td>14</td>
<td>Female</td>
<td>12</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Good</td>
</tr>
<tr>
<td>15</td>
<td>Female</td>
<td>9</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Good</td>
</tr>
<tr>
<td>16</td>
<td>Female</td>
<td>11</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Good</td>
</tr>
<tr>
<td>17</td>
<td>Male</td>
<td>10</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Bad</td>
</tr>
<tr>
<td>18</td>
<td>Male</td>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Good</td>
</tr>
<tr>
<td>19</td>
<td>Female</td>
<td>9</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Bad</td>
</tr>
<tr>
<td>20</td>
<td>Female</td>
<td>12</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Bad</td>
</tr>
<tr>
<td>21</td>
<td>Female</td>
<td>9</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Bad</td>
</tr>
<tr>
<td>22</td>
<td>Male</td>
<td>6</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Bad</td>
</tr>
<tr>
<td>23</td>
<td>Female</td>
<td>7</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Bad</td>
</tr>
<tr>
<td>24</td>
<td>Male</td>
<td>12</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Good</td>
</tr>
<tr>
<td>25</td>
<td>Male</td>
<td>9</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Good</td>
</tr>
<tr>
<td>26</td>
<td>Female</td>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Good</td>
</tr>
<tr>
<td>No</td>
<td>TW BCS ×10³/µl</td>
<td>TRBC CS ×10⁶/µl</td>
<td>Hb g/dl</td>
<td>Hb %</td>
<td>PCV %</td>
<td>MCV fl</td>
<td>MC Hpg</td>
<td>MC HC %</td>
</tr>
<tr>
<td>----</td>
<td>----------------</td>
<td>------------------</td>
<td>--------</td>
<td>------</td>
<td>-------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td>1</td>
<td>9.1</td>
<td>1.70</td>
<td>6.4</td>
<td>44</td>
<td>21.2</td>
<td>124.7</td>
<td>37.6</td>
<td>30.2</td>
</tr>
<tr>
<td>2</td>
<td>20.0</td>
<td>2.40</td>
<td>7.6</td>
<td>52</td>
<td>24.3</td>
<td>102.3</td>
<td>31.7</td>
<td>31.3</td>
</tr>
<tr>
<td>3</td>
<td>4.1</td>
<td>1.07</td>
<td>3.4</td>
<td>23</td>
<td>10.9</td>
<td>102.9</td>
<td>31.8</td>
<td>31.2</td>
</tr>
<tr>
<td>4</td>
<td>11.8</td>
<td>2.38</td>
<td>9.2</td>
<td>62</td>
<td>29.2</td>
<td>122.7</td>
<td>38.7</td>
<td>31.5</td>
</tr>
</tbody>
</table>
| 5 | 7.6 | 1.95 | 6.5 | 44 | 19.9 | 103.0 | 33.3 | 32.7 | 385 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 6 | 4.4 | 1.14 | 3.7 | 25 | 11.8 | 103.5 | 32.5 | 31.4 | 71 | Marrow hypoplasia/aplasia | - | nonmeg aloblastic
| 7 | 13.0 | 2.58 | 8.5 | 58 | 27.2 | 105.4 | 32.9 | 31.3 | 203 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 8 | 5.6 | 2.55 | 9.1 | 62 | 30.2 | 118.0 | 35.6 | 30.1 | 255 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 9 | 6.4 | 2.62 | 8.7 | 59 | 26.7 | 102.9 | 33.2 | 32.6 | 329 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 10 | 2.5 | 2.00 | 7.2 | 49 | 21.9 | 109.5 | 36.0 | 32.9 | 13 | Marrow hypoplasia/aplasia | - | nonmeg aloblastic
| 11 | 25.9 | 1.63 | 5.0 | 34 | 18.1 | 111.0 | 30.7 | 27.6 | 158 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 12 | 15.8 | 2.66 | 8.9 | 61 | 27.8 | 104.5 | 33.5 | 32.0 | 302 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 13 | 16.7 | 1.71 | 5.8 | 39 | 18.5 | 108.2 | 33.9 | 31.4 | 353 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 14 | 10.0 | 1.69 | 5.6 | 38 | 17.7 | 104.7 | 33.1 | 31.6 | 445 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 15 | 10.7 | 2.27 | 7.5 | 51 | 23.6 | 104.0 | 33.0 | 31.8 | 364 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 16 | 10.1 | 2.40 | 8.1 | 55 | 24.3 | 102.3 | 33.8 | 33.3 | 424 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 17 | 14.8 | 2.21 | 7.2 | 49 | 22.4 | 102.4 | 32.6 | 32.1 | 290 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 18 | 17.4 | 2.55 | 8.2 | 56 | 25.9 | 102.6 | 32.2 | 31.7 | 423 | Macrocytosis with sickle shape macrocytosis | - | nonmeg aloblastic
| 19 | 10.5 | 1.89 | 6.2 | 42 | 19.2 | 102.6 | 32.8 | 32.3 | 484 | Macrocytosis with sickle cell macrocytosis | - | nonmeg aloblastic
<p>| 20 | 7.3 | 2.28 | 6.6 | 45 | 23.3 | 102.0 | 28.9 | 28.3 | 180 | macrocytosis | Marrow hypoplasia/aplasia | nonmegablastic |
| 21 | 5.4 | 2.82 | 9.2 | 62 | 30.0 | 106.0 | 32.0 | 30.6 | 54  | macrocytosis | Marrow hypoplasia/aplasia | nonmegablastic |
| 22 | 2.6 | 1.93 | 6.3 | 43 | 19.5 | 102.0 | 32.6 | 32.3 | 25  | macrocytosis | Marrow hypoplasia/aplasia | nonmegablastic |
| 23 | 25.7 | 1.70 | 5.7 | 39 | 19.1 | 112.4 | 33.5 | 29.8 | 323 | Macrocytosis with sickle shape | nonmegablastic |
| 24 | 2.5 | 0.82 | 2.8 | 19 | 9.0 | 109.8 | 34.1 | 31.1 | 14  | macrocytosis | Marrow hypoplasia/aplasia | nonmegablastic |
| 25 | 2.9 | 2.47 | 8.0 | 54 | 26.1 | 105.7 | 32.4 | 30.7 | 78  | macrocytosis | Marrow hypoplasia/aplasia | nonmegablastic |
| 26 | 2.2 | 0.88 | 3.1 | 21 | 9.4 | 106.8 | 35.2 | 33.0 | 14  | macrocytosis | Marrow hypoplasia/aplasia | nonmegablastic |
| 27 | 3.1 | 2.54 | 9.0 | 61 | 28.1 | 110.6 | 35.4 | 32.0 | 254 | Macrocytosis with sickle shape | Marrow hypoplasia/aplasia | nonmegablastic |
| 28 | 10.7 | 2.10 | 7.4 | 50 | 23.1 | 110.0 | 35.2 | 32.0 | 385 | Macrocytosis with sickle shape | Marrow hypoplasia/aplasia | nonmegablastic |
| 29 | 2.1 | 0.91 | 3.8 | 26 | 11.3 | 124.2 | 41.8 | 33.6 | 20  | Macrocytosis with hypersegmented neutrophil | Marrow hypoplasia/aplasia | megaloablastic |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>12.0</td>
<td>1.98</td>
<td>6.8</td>
<td>46</td>
<td>21.0</td>
<td>106.1</td>
<td>34.3</td>
<td>32.4</td>
<td>539</td>
</tr>
<tr>
<td>31</td>
<td>15.9</td>
<td>2.42</td>
<td>8.6</td>
<td>58</td>
<td>25.3</td>
<td>104.5</td>
<td>35.5</td>
<td>34.0</td>
<td>505</td>
</tr>
<tr>
<td>32</td>
<td>11.9</td>
<td>1.69</td>
<td>6.1</td>
<td>41</td>
<td>18.1</td>
<td>107.1</td>
<td>36.1</td>
<td>33.7</td>
<td>211</td>
</tr>
<tr>
<td>33</td>
<td>8.9</td>
<td>2.58</td>
<td>8.4</td>
<td>57</td>
<td>26.2</td>
<td>102.6</td>
<td>32.6</td>
<td>32.1</td>
<td>195</td>
</tr>
<tr>
<td>34</td>
<td>14.0</td>
<td>2.51</td>
<td>8.5</td>
<td>58</td>
<td>25.7</td>
<td>102.4</td>
<td>33.9</td>
<td>33.1</td>
<td>275</td>
</tr>
<tr>
<td>35</td>
<td>6.4</td>
<td>2.14</td>
<td>8.8</td>
<td>59</td>
<td>25.3</td>
<td>118.2</td>
<td>41.1</td>
<td>34.8</td>
<td>317</td>
</tr>
<tr>
<td>36</td>
<td>13.1</td>
<td>1.64</td>
<td>5.7</td>
<td>39</td>
<td>18.2</td>
<td>111.0</td>
<td>34.8</td>
<td>31.3</td>
<td>709</td>
</tr>
<tr>
<td>37</td>
<td>6.8</td>
<td>2.59</td>
<td>8.9</td>
<td>61</td>
<td>26.4</td>
<td>102.8</td>
<td>34.3</td>
<td>33.7</td>
<td>715</td>
</tr>
<tr>
<td>38</td>
<td>2.1</td>
<td>1.93</td>
<td>6.7</td>
<td>46</td>
<td>20.8</td>
<td>107.8</td>
<td>34.7</td>
<td>32.2</td>
<td>185</td>
</tr>
<tr>
<td>39</td>
<td>4.4</td>
<td>1.15</td>
<td>3.8</td>
<td>26</td>
<td>12.0</td>
<td>104.3</td>
<td>33.0</td>
<td>31.6</td>
<td>165</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>13.0</td>
<td>2.22</td>
<td>7.2</td>
<td>49</td>
<td>22.4</td>
<td>102.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>32.6</td>
<td>32.1</td>
<td>275</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Macrocytosis with sickle shape

- nonmegaloblastic

- x formation